PMID: 9187700Jun 1, 1997Paper

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

Urology
A BrufskyP Kantoff

Abstract

Androgen ablation with luteinizing hormone-releasing hormone (LHRH) agonists, orchiectomy, or oral estrogens has significant untoward sexual side effects. We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma of the prostate. In addition, we evaluated whether finasteride provided additional intraprostatic androgen blockade to flutamide. Twenty men with advanced prostate cancer were given flutamide, 250 mg orally three times daily. Serum prostate-specific antigen (PSA) values were measured weekly. At a nadir PSA value, finasteride, 5 mg orally every day, was added. PSA values were then measured weekly until a second nadir PSA value was achieved. Sexual function was evaluated at baseline, at the second nadir PSA value, and every 3 months thereafter. Testosterone, dihydrotestosterone (DHT), and dehydroepiandrostenedione (DHEA) levels were measured at baseline and at the first and second nadir PSA values. The median follow-up period was 16.9 months. Therapy failed in 1 patient with Stage D2 disease at 12 months, but an additional response to subsequent LHRH agonist therapy was observed. One patient developed National Cancer Institute grade 3 diarrhea a...Continue Reading

References

Dec 1, 1990·The Journal of Clinical Endocrinology and Metabolism·J Geller
Jul 1, 1991·Molecular and Cellular Endocrinology·F Labrie
Aug 17, 1989·The New England Journal of Medicine·E D CrawfordP J Goodman
Feb 1, 1987·British Journal of Urology·R Lundgren
Nov 15, 1984·The New England Journal of Medicine·UNKNOWN Leuprolide Study Group
Feb 1, 1996·The Journal of Clinical Endocrinology and Metabolism·R S RittmasterG Rowden

❮ Previous
Next ❯

Citations

Jun 27, 2002·Current Urology Reports·C R Pound, A W Partin
Jan 30, 2002·Clinica Chimica Acta; International Journal of Clinical Chemistry·Rachel S Rosenberg ZandEleftherios P Diamandis
Feb 1, 2003·Urology·Endre Z Neulander, Mark S Soloway
Feb 23, 1999·The Urologic Clinics of North America·D K OrnsteinG L Andriole
Sep 10, 2003·Current Problems in Cancer·Judd W Moul
Sep 5, 2003·Urologic Oncology·Beth A Hellerstedt, Kenneth J Pienta
Feb 14, 2006·Nature Clinical Practice. Urology·John F Ward, Judd W Moul
Mar 5, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Tamra E MeyerAnn W Hsing
Dec 1, 2007·Clinical Interventions in Aging·Steven J HudakIan M Thompson
Mar 6, 2007·Asian Journal of Andrology·Singh RajenderKumarasamy Thangaraj
Sep 25, 2014·Journal of Geriatric Oncology·Deepak KilariSupriya Gupta Mohile
Feb 28, 2001·Expert Opinion on Investigational Drugs·K A Harris, E J Small
Oct 19, 2000·Cancer Investigation·E Klein, R Drecier
May 8, 2000·The Journal of Urology·J W Moul
Jun 1, 2004·Expert Review of Pharmacoeconomics & Outcomes Research·Sven D'haese, Andrew Bottomley
May 31, 2002·Expert Opinion on Pharmacotherapy·Kris E Gaston, David K Ornstein
Mar 11, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Osmar Luiz Magalhães OliveiraVera Maria Treis Trindade
Jul 1, 2007·Current Therapeutic Research, Clinical and Experimental·Fatma Al-Saeedi
Jun 9, 2001·The Journal of Clinical Endocrinology and Metabolism·L WestbergE Eriksson
Feb 27, 1999·Endocrine Reviews·E RuijterJ Schalken

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.